BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32433536)

  • 1. Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells.
    Walsby-Tickle J; Gannon J; Hvinden I; Bardella C; Abboud MI; Nazeer A; Hauton D; Pires E; Cadoux-Hudson T; Schofield CJ; McCullagh JSO
    Commun Biol; 2020 May; 3(1):247. PubMed ID: 32433536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
    Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
    J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, gliomas, and IDH1.
    Smeitink J
    N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive in vivo assessment of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Yoshihara HA; Danforth OM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Nat Commun; 2013; 4():2429. PubMed ID: 24019001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
    Fujiwara H; Tateishi K; Misumi K; Hayashi A; Igarashi K; Kato H; Nakatsuka T; Suzuki N; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Kogure H; Nakai Y; Isayama H; Hasegawa K; Fukayama M; Soga T; Koike K
    Sci Rep; 2019 Dec; 9(1):18859. PubMed ID: 31827136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
    Navis AC; Niclou SP; Fack F; Stieber D; van Lith S; Verrijp K; Wright A; Stauber J; Tops B; Otte-Holler I; Wevers RA; van Rooij A; Pusch S; von Deimling A; Tigchelaar W; van Noorden CJ; Wesseling P; Leenders WP
    Acta Neuropathol Commun; 2013 May; 1():18. PubMed ID: 24252742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
    Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
    Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic alteration in tumorigenesis.
    Yang H; Xiong Y; Guan K
    Sci China Life Sci; 2013 Dec; 56(12):1067-75. PubMed ID: 24114443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
    Liu S; Cadoux-Hudson T; Schofield CJ
    Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
    Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ
    Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Fiehn O; Showalter MR; Schaner-Tooley CE; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26943899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
    Izquierdo-Garcia JL; Viswanath P; Eriksson P; Cai L; Radoul M; Chaumeil MM; Blough M; Luchman HA; Weiss S; Cairncross JG; Phillips JJ; Pieper RO; Ronen SM
    Cancer Res; 2015 Aug; 75(15):2999-3009. PubMed ID: 26045167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.